Cargando…

A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program

BACKGROUND: Oritavancin is a lipoglycopeptide used in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults. To characterize its use in patients in the postapproval setting, a patient registry was developed. METHODS: Data collected in an ongoing retrospective observ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Redell, Mark, Moeck, Greg, Lucasti, Christopher, Durso, Stephanie, Kennedy, Cynthia, Fusaro, Karen, Loutit, Jeff, Dudley, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016411/ https://www.ncbi.nlm.nih.gov/pubmed/29977954 http://dx.doi.org/10.1093/ofid/ofy051

Ejemplares similares

Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials
por: Lodise, Thomas P., et al.
Publicado: (2017)

The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections
por: Redell, Mark, et al.
Publicado: (2019)

Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties
por: Hoover, Randall K, et al.
Publicado: (2022)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

443. The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin for Treatment of Gram-Positive Infections
por: Redell, Mark, et al.
Publicado: (2019)

1331 The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Corey, Ralph, et al.
Publicado: (2014)

Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas P, et al.
Publicado: (2019)

Real-World Evidence Studies of Oritavancin Use in Gram-Positive Infections Augment Randomized Controlled Trials to Address Clinical and Economic Outcomes
por: Redell, Mark
Publicado: (2020)

Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections
por: Moenster, Ryan P, et al.
Publicado: (2023)

Real-World Use of Oritavancin for the Treatment of Osteomyelitis
por: Scoble, Patrick J., et al.
Publicado: (2020)

Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections
por: Stewart, Cassie L., et al.
Publicado: (2017)

Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials
por: Alexander, Elizabeth L., et al.
Publicado: (2017)

338 Prevalence, Mortality and Outcomes of Antibiotic Therapy of Multi-Drug Resistant Acinetobacter baumannii
por: Lapensee, Kenneth T., et al.
Publicado: (2014)

Real-World Evidence for Oritavancin Use in Gram-Positive Infections
Publicado: (2020)

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
por: Deck, Daniel H., et al.
Publicado: (2016)

Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
por: Deck, Daniel H., et al.
Publicado: (2016)

1015. Real World Use of Dalbavancin and Oritavancin for Optimized Outpatient Antimicrobial Therapy in Patients Inappropriate for Standard Therapy
por: Weichman, Brittani, et al.
Publicado: (2022)

1928. Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin (ORI) or Vancomycin (VAN) for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas, et al.
Publicado: (2018)

Antimicrobial Management of Respiratory Infections in Severe Acute Respiratory Syndrome Coronavirus 2 Patients: Clinical and Antimicrobial Stewardship Programs Conundrums
por: Goldstein, Ellie J C, et al.
Publicado: (2020)

Real-world Use of Mold-Active Triazole Prophylaxis in the Prevention of Invasive Fungal Diseases: Results From a Subgroup Analysis of a Multicenter National Registry
por: Nguyen, M Hong, et al.
Publicado: (2023)

The Clinical Efficacy of Multidose Oritavancin: A Systematic Review
por: Baiardi, Giammarco, et al.
Publicado: (2023)

Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19
por: Webb, Brandon J, et al.
Publicado: (2021)

Oritavancin polymethylmethacrylate (PMMA)—compressive strength testing and in vitro elution
por: Schmidt-Malan, Suzannah M., et al.
Publicado: (2019)

Distinct Effectiveness of Oritavancin against Tolerance-Induced Staphylococcus aureus
por: Berti, Andrew D., et al.
Publicado: (2020)

1420. Successful Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study
por: Alam, Imtiaz, et al.
Publicado: (2016)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

The Yield and Consistency of the Detection of SARS-CoV-2 in Multiple Respiratory Specimens
por: Zhang, Haixia, et al.
Publicado: (2020)

Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
por: Brade, Karrine D., et al.
Publicado: (2016)

A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis
por: Rose, Warren E., et al.
Publicado: (2020)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

1606. Distinct Effectiveness of Oritavancin Against Tolerance-Induced Staphylococcus aureus
por: Harven, Lauren, et al.
Publicado: (2020)

Assessment of Infectious Diseases Risks From Dental Aerosols in Real-World Settings
por: Choudhary, Shruti, et al.
Publicado: (2022)

Demonstration of Human Fetal Bone Morphology with MR Imaging: A Preliminary Study
por: Matsubara, Yoshiko, et al.
Publicado: (2019)

Real-world Time to Positivity of 2 Widely Used Commercial Blood Culture Systems in Patients With Severe Manifestations of Sepsis: An Analysis of the FABLED Study
por: Butler-Laporte, Guillaume, et al.
Publicado: (2020)

Impact of Procalcitonin-Guided Antibiotic Management on Antibiotic Exposure and Outcomes: Real-world Evidence
por: Broyles, Michael R
Publicado: (2017)

Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis
por: Cain, Alexander R, et al.
Publicado: (2021)

Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
por: de la Villa, Sofía, et al.
Publicado: (2023)

A Qualitative Study of the Real-world Experiences of Infectious Diseases Fellows Regarding Antibiotic Stewardship
por: Morgan, Jake R, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vsn54li1iq0e6el1d63pmkcr25